Why Arcturus Therapeutics Stock Skyrocketed Today

1 min read

Shares of Arcturus Therapeutics (NASDAQ: ARCT) were skyrocketing 40.9% higher as of 3:10 p.m. EST on Thursday. The huge gain came after Wells Fargo analyst Jim Birchenough initiated coverage on the stock with an overweight rating. He also set a $118 price target — a premium of 139% to Arcturus’ closing price on Wednesday.

Arcturus’ shares plunged in December after the company announced updated results from a phase 2 study of COVID-19 vaccine candidate ARCT-021 that disappointed investors. So why is Birchenough so bullish about the biotech stock?

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Investor Urges MGM Resorts to Sell Off Stake in China Operations

Next Story

Why Etsy Stock Surged 301% in 2020

Latest from Blog